Candriam S.C.A. Has $13 Million Stock Position in Annexon, Inc. (NASDAQ:ANNX)

Candriam S.C.A. lifted its stake in Annexon, Inc. (NASDAQ:ANNX) by 15.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 2,534,230 shares of the company’s stock after buying an additional 341,431 shares during the period. Candriam S.C.A.’s holdings in Annexon were worth $13,001,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Arizona State Retirement System bought a new position in Annexon during the fourth quarter worth about $102,000. Charles Schwab Investment Management Inc. grew its holdings in Annexon by 1.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 743,795 shares of the company’s stock worth $3,816,000 after purchasing an additional 11,579 shares during the period. Mutual of America Capital Management LLC grew its holdings in Annexon by 56.2% during the fourth quarter. Mutual of America Capital Management LLC now owns 1,029,680 shares of the company’s stock worth $5,282,000 after purchasing an additional 370,426 shares during the period. Bank of New York Mellon Corp grew its holdings in Annexon by 2.8% during the fourth quarter. Bank of New York Mellon Corp now owns 230,546 shares of the company’s stock worth $1,183,000 after purchasing an additional 6,226 shares during the period. Finally, New York State Common Retirement Fund grew its holdings in Annexon by 143.4% during the fourth quarter. New York State Common Retirement Fund now owns 34,479 shares of the company’s stock worth $177,000 after purchasing an additional 20,311 shares during the period.

Annexon Trading Up 3.0 %

NASDAQ ANNX opened at $2.76 on Friday. Annexon, Inc. has a 1-year low of $2.30 and a 1-year high of $8.40. The company has a 50 day moving average of $3.75 and a 200-day moving average of $5.34. The company has a market cap of $294.20 million, a price-to-earnings ratio of -2.63 and a beta of 1.14.

Annexon (NASDAQ:ANNX) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). On average, equities research analysts forecast that Annexon, Inc. will post -0.96 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ANNX. Needham & Company LLC restated a “buy” rating and set a $16.00 price objective on shares of Annexon in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Annexon in a report on Tuesday, December 17th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $15.80.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.